Observational studyDeutsches Arzteblatt international2025
The Probability of Remaining Under Active Surveillance for Localized Prostate Cancer: An Analysis of Young Patients in the Framework of the Multicenter ProjuMa Registry Study.
Observational study in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Benefits of Testosterone Treatment in Prostate Cancer.Deutsches Arzteblatt international · 2025Article
- Important Studies Were not Mentioned.Deutsches Arzteblatt international · 2025Article
- In Reply.Deutsches Arzteblatt international · 2025Article
- Prostate Cancer: Early Detection, Diagnostic Evaluation, and Individualized Treatment Decisions.Deutsches Arzteblatt international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfter a diagnosis of prostate cancer, the 15-year cancer-specific survival probability is high; in suitable patients, active surveillance lessens the side effects of curative treatment. Limited evidence is available on the continuation of active surveillance in young prostate cancer patients in Germany.
methodsUsing data that were reported, as required by law, to the population-based cancer registries of the German federal states of North Rhine-Westphalia, Baden-Württemberg, and Rhineland- - Palatinate, we studied the course of 732 patients under 60 years of age who were under active surveillance after receiving a diagnosis of low-risk localized prostate cancer (ISUP grade 1 or 2) in the years 2016-2021.
resultsThe median duration of follow-up was 28 months. 64% [61%; 68%] of the patients were still under active surveillance at two years; this was true for 66% [62%; 70%] of those with ISUP grade 1 disease, 46% [37%; 58%] of those with ISUP grade 2 disease, and 72% [63%; 83%] of those for whom no Gleason grading was available. 62% of discontinuations occurred without any documented progression and without a documented patient-initiated decision.
conclusionThe two-year probability of young prostate cancer patients remaining under active surveillance was lower in Germany than in other countries. The cancer registries mostly received no information concerning the clinical rationale for the discontin uations. The potentially incomplete reporting of reasons for discontinuing active surveillance suggests that clinical reporting practices should be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.